INMB INmune Bio Inc.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product cand…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 INmune Bio (INMB) Q2 2026 Earnings Call Transcript Ebstracel nears UK filing as XPro shows Alzheimer's biomarker progress. | ||
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ... INmune Bio Inc (INMB) secures MHRA alignment and advances commercial manufacturing, positioning for UK MAA submission while reducing net loss to $1.3 million. | ||
 INmune Bio, Inc. Q2 2026 Earnings Call Summary Moby summary of INmune Bio, Inc.'s Q2 2026 earnings call | ||
 INmune Bio Q2 Earnings Call Highlights INmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second quarter of 2027. Ch | ||